JP2011510910A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510910A5
JP2011510910A5 JP2010528504A JP2010528504A JP2011510910A5 JP 2011510910 A5 JP2011510910 A5 JP 2011510910A5 JP 2010528504 A JP2010528504 A JP 2010528504A JP 2010528504 A JP2010528504 A JP 2010528504A JP 2011510910 A5 JP2011510910 A5 JP 2011510910A5
Authority
JP
Japan
Prior art keywords
group
groups
compound
alkyl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528504A
Other languages
English (en)
Japanese (ja)
Other versions
JP5416125B2 (ja
JP2011510910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/003263 external-priority patent/WO2009060305A2/en
Publication of JP2011510910A publication Critical patent/JP2011510910A/ja
Publication of JP2011510910A5 publication Critical patent/JP2011510910A5/ja
Application granted granted Critical
Publication of JP5416125B2 publication Critical patent/JP5416125B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528504A 2007-10-12 2008-10-10 免疫アジュバントとして有用な糖脂質の類似体 Expired - Fee Related JP5416125B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97978507P 2007-10-12 2007-10-12
US60/979,785 2007-10-12
PCT/IB2008/003263 WO2009060305A2 (en) 2007-10-12 2008-10-10 Analogues of glycolipids useful as immunoadjuvants

Publications (3)

Publication Number Publication Date
JP2011510910A JP2011510910A (ja) 2011-04-07
JP2011510910A5 true JP2011510910A5 (cg-RX-API-DMAC10.html) 2012-11-22
JP5416125B2 JP5416125B2 (ja) 2014-02-12

Family

ID=40626266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528504A Expired - Fee Related JP5416125B2 (ja) 2007-10-12 2008-10-10 免疫アジュバントとして有用な糖脂質の類似体

Country Status (8)

Country Link
US (1) US8697659B2 (cg-RX-API-DMAC10.html)
EP (1) EP2483287B1 (cg-RX-API-DMAC10.html)
JP (1) JP5416125B2 (cg-RX-API-DMAC10.html)
CN (1) CN102066394B (cg-RX-API-DMAC10.html)
AU (1) AU2008326138B2 (cg-RX-API-DMAC10.html)
CA (1) CA2702344C (cg-RX-API-DMAC10.html)
ES (1) ES2574825T3 (cg-RX-API-DMAC10.html)
WO (1) WO2009060305A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471518B1 (en) 2009-05-18 2017-08-23 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) * 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
KR101675657B1 (ko) * 2012-03-19 2016-11-11 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 탄수화물-당지질 컨쥬게이트 백신
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
WO2022256467A1 (en) * 2021-06-02 2022-12-08 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods comprising deoxy-pentitols

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW261533B (cg-RX-API-DMAC10.html) * 1992-07-16 1995-11-01 Kirin Brewery
AU2002327097B2 (en) * 2001-08-16 2007-05-24 Japan As Represented By President Of National Centre Of Neurology And Psychiatry Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
AU2005280163B2 (en) * 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions

Similar Documents

Publication Publication Date Title
AU740663B2 (en) Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP5416125B2 (ja) 免疫アジュバントとして有用な糖脂質の類似体
EP3197907B1 (en) Vaccines against streptococcus pneumoniae serotype 8
CN114040918B (zh) 皂苷缀合物及含其的疫苗或药物组合物
KR100885008B1 (ko) 신규 면역효과기 화합물
JP6622804B2 (ja) ストレプトコッカス ニューモニアエ(Streptococcus pneumoniae)血清型4に対するワクチン
EP3274358B1 (en) Vaccine against carbapenem-resistantklebsiella pneumoniae
TW201442739A (zh) 過敏疾病治療藥
CA2842136C (en) Multivalent [beta]-1-2-linked mannose oligosaccharides as immunostimulatory compounds and uses thereof
CN114126419A (zh) 基于皂苷的疫苗佐剂
RU2289585C2 (ru) Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
HK40061148A (en) Saponin-based vaccine adjuvants
EP3000820A1 (en) Synthetic vaccines against Streptococcus pneumoniae serotype 8
HK1029120B (en) Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
HK1242329B (en) Vaccines against streptococcus pneumoniae serotype 8
HK1242329A1 (en) Vaccines against streptococcus pneumoniae serotype 8
BRPI0711235A2 (pt) composto, composição farmacêutica, método para induzir seletivamente uma resposta imune tipo th-1 em um mamìfero, método para tratar uma doença que requer uma resposta tipo th-1, método para aumentar a imunogenicidade para um antìgeno em um mamìfero e método para preparar um composto
MXPA99010262A (en) Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors